Leukapheresis Device Market Report 2025

The leukapheresis device market size has grown strongly in recent years. It will grow from $0.65 billion in 2024 to $0.7 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth during the historical period can be credited to the rising demand for personalized medicine, enhanced emphasis on research and development, an increasing number of clinical trials, a growing elderly population, and the expanding adoption of minimally invasive procedures.

The leukapheresis device market size is expected to see strong growth in the next few years. It will grow to $0.94 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth projected for the forecast period can be attributed to the rising prevalence of blood-related disorders, increasing incidence of cancer, growing demand for peripheral blood stem cell collection, expanding use of leukapheresis in cellular therapies, and heightened investments in regenerative medicine and immunotherapy. Major trends anticipated during this period include technological innovations in apheresis devices, integration of automation and digital technologies, progress in point-of-care leukapheresis systems, advancements in closed-loop leukapheresis technologies, and technology-enhanced improvements in cell separation efficiency.

The increasing prevalence of blood-related disorders is anticipated to drive the growth of the leukapheresis device market. These disorders affect the structure or function of blood cells, leading to complications with oxygen transport, immune function, and blood clotting. One of the primary reasons for this rise is the aging population, which is more prone to developing conditions such as anemia, leukemia, and other hematologic diseases. Leukapheresis devices play a crucial role in managing these conditions by selectively removing excess or abnormal white blood cells from the bloodstream, thereby easing symptoms and lowering the risk of complications in illnesses like leukemia and autoimmune disorders. For example, in May 2024, the Leukaemia Foundation, an Australian non-profit organization, reported that in 2022, approximately 19,403 Australians were diagnosed with blood cancers, including leukemia, lymphoma, and myeloma. This equates to around 53 new cases each day, or one diagnosis every 27 minutes. Presently, nearly 135,000 Australians are living with a blood cancer or disorder, and projections indicate this number could exceed 275,000 by 2035. This upward trend in blood-related conditions is contributing significantly to the growing demand for leukapheresis devices.

Key players in the leukapheresis device market are increasingly investing in regional production capabilities to improve access to therapeutic devices and align with national healthcare strategies. Establishing local manufacturing facilities helps to streamline supply chains, reduce reliance on imports, and enhance the affordability and availability of advanced blood and cell collection systems. For instance, in November 2024, Terumo Blood and Cell Technologies, a US-based medical technology firm, collaborated with its China-based subsidiary, Terumo Medical Products (Hangzhou) Co., Ltd., to initiate localized production in Hangzhou. This initiative focuses on producing vital leukapheresis products, such as the Trima Accel Automated Blood Collection System and the Spectra Optia Apheresis System, which are widely used in China for procedures including therapeutic apheresis, stem cell collection, and blood component separation.

In July 2022, Discovery Life Sciences, a US-based provider of highly characterized human biospecimens, completed the acquisition of AllCells LLC for an undisclosed sum. The acquisition is intended to create a comprehensive, scalable solution offering clients consistent access to high-quality human cellular starting materials along with integrated analytical services to support the development of cell and gene therapies. AllCells LLC, also based in the US, is a biotechnology company that specializes in leukapheresis devices for the targeted collection of blood cells.

Major players in the leukapheresis device market are Fresenius SE and Co. KGaA, Asahi Kasei Medical Co. Ltd, Baxter International Inc., Grifols S.A., TERUMO BCT INC., Kaneka Corporation, Charles River Laboratories International Inc., Mallinckrodt Pharmaceuticals, Nikkiso Co. Ltd., Haemonetics Corporation, Miltenyi Biotec GmbH, Macopharma, Precision for Medicine Inc., B. Braun Melsungen AG, BioIVT LLC, AllCells LLC, Kawasumi Laboratories Inc., Beijing Zksk Technology Co. Ltd., Puriblood Medical Co. Ltd, and Medica S.p.A.

North America was the largest region in the leukapheresis device market in 2024. The regions covered in leukapheresis device report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the leukapheresis device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The leukapheresis device market consists of sales of leukapheresis software and monitoring systems, blood flow controllers and pumps, and centrifuge rotors and tubing sets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The leukapheresis device market research report is one of a series of new reports that provides leukapheresis device market statistics, including the leukapheresis device industry's global market size, regional shares, competitors with the leukapheresis device market share, detailed leukapheresis device market segments, market trends and opportunities, and any further data you may need to thrive in the leukapheresis device market. This leukapheresis device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

A leukapheresis device is a specialized medical tool designed to selectively isolate and collect white blood cells (leukocytes) from the blood of a patient or donor through centrifugation or filtration methods. It serves an essential function in therapies such as leukemia treatment, stem cell transplantation, and autoimmune disorder management, and is also utilized in clinical research and diagnostic procedures.

The primary categories of leukapheresis devices include therapeutic leukapheresis, cytapheresis, stem cell collection, research applications, leukapheresis columns and cell separators, leukapheresis disposables, and apheresis devices. Therapeutic leukapheresis is a medical technique employed to extract surplus or abnormal white blood cells from the bloodstream, aiming to alleviate symptoms or avoid related complications. These systems comprise various elements, including leukapheresis machines, blood collection sets, medical consumables, and filtration components. The diverse group of end users includes hospitals, academic and research organizations, pharmaceutical and biotechnology firms, blood centers, and providers of blood components.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.